Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAT + IL-2 in Leukemia and Lymphoma
NCT00002681Phase 2Completed
- Sponsor
- Roger Williams Medical Center
- Start
- Jul 1995
- Primary completion
- Sep 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclizumab in Hodgkin lymphoma (HL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), sponsored by Roger Williams Medical Center. Primary endpoint: Safety and tolerability of HAT and IL-2. Started Jul 1995; status: completed.
02
Drugs
daclizumab
03
Conditions
Hodgkin lymphoma (HL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00002681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002681.